Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin
Proper hydration keeps your stool softer and easier to pass
Before & After: Setting Realistic Tirzepatide Expectations The ideal candidate for tirzepatide therapy is typically someone with a BMI of 30 or higher, or a BMI of 27 or higher accompanied by weight-related comorbidities such as hypertension, high cholesterol, insulin resistance, or type 2 diabetes
The tirzepatide doses of 10 and/or 15 mg demonstrated superiority compared to placebo for the coprimary endpoints percentage body weight reductions from baseline at week 72 and the proportion of patients achieving 5% body weight reduction at week 72
Studies on semaglutide have not shown an increased risk of blood clots in users, and its generally considered safe in this regard
Severe or persistent vomiting or diarrhea requires medical attention due to the risk of dehydration and potential acute kidney injury